Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in

Amarin spent years, millions of dollars and a lot of willpower proving its fish oil-based drug Vascepa really could cut the risk of heart attacks, strokes and other cardiovascular problems. To make that effort pay off, it needs to keep that proof to itself. That's just what the drugmaker did in settling two lawsuits with fish oil supplement manufacturers who'd allegedly co-opted the results of Amarin's landmark Reduce-It trial.
Read more...

;